1-cyclopentyl-N-methylmethanamine hydrochloride | 666262-50-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-cyclopentyl-N-methylmethanamine hydrochloride
• 英文别名: N-(cyclopentylmethyl)-N-methylamine hydrochloride；(Cyclopentylmethyl)methylamine hydrochloride；1-cyclopentyl-N-methylmethanamine;hydrochloride
• CAS: 666262-50-6
• 化学式: C₇H₁₅N*ClH
• mdl: MFCD14705820
• 分子量: 149.664
• InChiKey: YRIMTMONXNUNNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.48
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-cyclopentyl-N-methylmethanamine hydrochloride 在 磺酰氯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (cyclopentylmethyl)(methyl)sulfamoyl chloride
  参考文献：
  名称：

  TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS

  摘要：

  本发明提供了式(I)的化合物： 或其立体异构体、互变异构体或药用可接受的盐或溶剂化物，其中所有变量均如本文所述定义。这些化合物是选择性的LPA受体抑制剂。

  公开号：

  US20190185446A1

文献信息

• [EN] COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE<br/>[FR] COMBINAISON DE MODULATEURS DU CB2 ET D'INHIBITEURS DE LA PDE4 UTILISEE EN MEDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005074939A1

  公开（公告）日：2005-08-18

  Combination of one or more CB2 modulators such as a compound of formula (I), (II) and (III); and one more PDE4 inhibitors are useful of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflamatory disorder, pain, rheumatoid.

  一种或多种CB2调节剂的组合，例如式(I)、(II)和(III)的化合物；以及一种或多种PDE4抑制剂对于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病，如免疫紊乱、炎症性疾病、疼痛、类风湿等症状是有用的。
• [EN] PYRIMIDINE DERIVATIVES AND THEIR USE AS CB2 MODULATORS<br/>[FR] DERIVES DE PYRIMIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS CB2
  申请人：GLAXO GROUP LTD

  公开号：WO2004018433A1

  公开（公告）日：2004-03-04

  This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  这涉及到新型嘧啶衍生物，含有这些化合物的制药组合物，以及它们在治疗疾病中的应用，特别是疼痛，这些疾病直接或间接地由大麻素受体活性的增加或减少引起。
• Pyrimidine derivatives and their use as CB2 modulators
  申请人：Eatherton John Andrew

  公开号：US20060293354A1

  公开（公告）日：2006-12-28

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病，特别是由大麻素受体活性的增加或减少直接或间接引起的疼痛方面的用途。
• Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine
  申请人：Brown Andrew James

  公开号：US20080132505A1

  公开（公告）日：2008-06-05

  Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.

  一种由一种或多种CB2调节剂和一种或多种PDE4抑制剂组合而成的治疗方法，用于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病。
• Pyrimidine Derivatives And Their Use As CB2 Modulators
  申请人：Eatherton Andrew John

  公开号：US20100041654A1

  公开（公告）日：2010-02-18

  This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新的嘧啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病中的应用，特别是治疗由于大麻素受体活性增加或减少而直接或间接引起的疼痛等疾病。